Patients could benefit from bespoke cancer-fighting treatments with fewer side effects thanks to a new partnership between a biotech company and a UK university.
The University of Leicester has joined forces with Cambridge-based Isogenica to develop new immunotherapies – a process where the patient’s immune system is helped to fight cancer – which will be tested on a ‘virtual patient’.
The virtual patient will be created in the laboratory, by taking samples of a patient’s own tumour cells and immune system, and will then be presented with a range of new immunotherapies developed by the…
Alexion, AstraZeneca’s rare disease subsidiary, is acquiring a portfolio of preclinical gene therapy programs from Pfizer. The deal will bring a number of novel adeno-associated virus (AAV) capsids to Alexion and help build on AstraZeneca’s capabilities in genomic medicine.
Under the agreement, Alexion will purchase and license the assets of Pfizer’s early-stage rare disease gene therapy portfolio for a total of up to $1 billion, plus tiered royalties on sales. Alexion plans to close the transaction in Q3 2023.
Marc Dunoyer, CEO, Alexion, AstraZeneca Rare Disease, said, “Today’s…
Progressive plans for the next phase of Manchester Science Park’s masterplan development have today been approved by Manchester City Council. The scheme will see Bruntwood SciTech, a 50:50 joint venture between Bruntwood and Legal & General, deliver a £60m redevelopment of the Park’s existing Greenheys building, bringing forward 131,000 sq ft of highly specialist world-class lab space.
The redevelopment by the UK’s leading property provider dedicated to the growth of the science and technology sector forms the third phase of Bruntwood SciTech’s…
Cambridge, United Kingdom, 26th July 2023 / Domainex Ltd., a leading, integrated medicines research services partner and recent recipient of the King’s Award for Enterprise in International Trade, announces the purchase of its third, multi-channel Malvern Panalytical WAVEdelta system, powered by Creoptix technology. Simultaneously, Domainex announces the expansion of its biophysical suite of technologies through the purchase of a Malvern Panalytical PEAQ-ITC instrument with MicroCal technology.
The addition of a third WAVEdelta system to the Domainex portfolio provides the company with…
San Diego, CA - BioMed Realty, a leading provider of real estate solutions to the life science and technology industries, announced that Charlie Piscitello has joined the company as Chief People Officer.
In this role, Mr. Piscitello will lead the Company’s human resource related functions, including talent management, culture, and diversity, equity, and inclusion, reporting to Tim Schoen, CEO of BioMed Realty, and will be based in BioMed Realty’s San Diego headquarters.
“We are thrilled to welcome Charlie to BioMed Realty, where he will lead our continued success in talent recruitment,…
INDIANAPOLIS, July 27, 2023 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results of two phase 3 tirzepatide studies in adults with obesity or overweight with weight-related comorbidities, excluding type 2 diabetes. SURMOUNT-3 and SURMOUNT-4 met all primary and key secondary objectives for tirzepatide compared to placebo. Across SURMOUNT-3 and SURMOUNT-4, participants on tirzepatide following intensive lifestyle intervention or with continued tirzepatide treatment, achieved up to 26.6% mean weight loss, for the efficacy estimandi.
The overall safety…
Biocair recently spoke at two industry events, Gene Therapy Development & Manufacturing 2023 and On Helix 2023, where the company provided insight on how to mitigate risk in the cell and gene therapy supply chain.
Life science logistics requires complete visibility, expertise and reliability due to the sensitive nature of the time- and temperature-sensitive materials in transit. Biocair is a leading pharmaceutical, biotech and life science logistics provider with over 35 years of experience. Over the past couple of years, the business has invested heavily in cell and gene therapy…
Cambridge, UK - 26 July 2023 - Maxion Therapeutics (“Maxion”), the biotechnology company developing antibody-based drugs for previously untreatable ion channel- and GPCR-driven diseases, is relocating to The Works, Unity Campus, located just outside Cambridge, UK. The company is moving from its previous site at the Babraham Research Campus to an over 7,600 sq ft facility to support further growth.
The move follows Maxion’s successful USD $16 million (GBP £13 million) Series A fundraise in February 2023, and the award of £2 million Innovate UK funding, to support the development of novel…
Welcome News:
One Nucleus welcomes the Government's support of Cambridge to continue developing as a destination to attract global investment and talent in life sciences through plans to create aspirational housing and communities for those employed in the sector.
Housing to Match Aspiration:
The focus on home ownership whilst important may not in itself deliver the correct balance of residential accommodation. In innovation-driven industries such as ours, a significant proportion of the workforce are international, many of whom seeing the attraction of Cambridge as the next step, but perhaps…
Having recently attended the London Stem Cell Conference, Oliver Herd, a trainee patent attorney at IP law firm Appleyard Lees IP LLP, reflects on some of the current activity in the stem cell field and how products, methods and consumables can be protected in Europe.
On 27 June 2023, Magdalena Zernicka-Goetz was awarded the Ogawa-Yamanaka Stem Cell prize for her work in determining the mechanisms that drive mammalian embryo development through the creation of in vitro 3D models. These models, which develop brain structures and a beating heart, appeared in Nature’s list of “Seven…